Precision BioSciences (NASDAQ:DTIL) Director Acquires $16,384.52 in Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) Director Geno Germano purchased 2,609 shares of the company’s stock in a transaction that occurred on Friday, September 25th. The stock was bought at an average cost of $6.28 per share, for a total transaction of $16,384.52. Following the purchase, the director directly owned 47,492 shares in the company, valued at $298,249.76. This trade represents a 5.81% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Precision BioSciences Stock Performance

NASDAQ:DTIL opened at $6.33 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 12.82 and a current ratio of 12.82. The company has a fifty day moving average of $7.30 and a two-hundred day moving average of $7.21. The stock has a market capitalization of $174.71 million, a PE ratio of -2.26 and a beta of 1.27. Precision BioSciences, Inc. has a fifty-two week low of $3.53 and a fifty-two week high of $9.62.

Precision BioSciences (NASDAQ:DTIL) last announced its earnings results on Thursday, August 6th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.46). Precision BioSciences had a negative net margin of 96.73% and a negative return on equity of 72.52%. As a group, research analysts forecast that Precision BioSciences, Inc. will post -3.33 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have commented on DTIL. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precision BioSciences in a research note on Wednesday, August 5th. HC Wainwright restated a “buy” rating on shares of Precision BioSciences in a research report on Monday, August 3rd. Oppenheimer started coverage on Precision BioSciences in a research note on Tuesday, June 9th. They issued an “outperform” rating and a $20.00 price target on the stock. Finally, Wall Street Zen cut Precision BioSciences from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Precision BioSciences presently has a consensus rating of “Moderate Buy” and an average target price of $32.25.

Hedge Funds Weigh In On Precision BioSciences

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Octagon Capital Advisors LP grew its stake in Precision BioSciences by 16.6% during the 1st quarter. Octagon Capital Advisors LP now owns 2,236,732 shares of the company’s stock valued at $12,302,000 after acquiring an additional 318,737 shares in the last quarter. Empery Asset Management LP acquired a new stake in Precision BioSciences in the 4th quarter valued at about $9,130,000. Affinity Asset Advisors LLC purchased a new position in Precision BioSciences in the 1st quarter worth approximately $3,289,000. Corient Private Wealth LP lifted its stake in Precision BioSciences by 70.4% in the 2nd quarter. Corient Private Wealth LP now owns 245,058 shares of the company’s stock worth $1,926,000 after purchasing an additional 101,206 shares in the last quarter. Finally, Squarepoint Ops LLC boosted its holdings in shares of Precision BioSciences by 212.7% during the 2nd quarter. Squarepoint Ops LLC now owns 137,106 shares of the company’s stock worth $1,078,000 after purchasing an additional 93,258 shares during the last quarter. 37.99% of the stock is currently owned by institutional investors and hedge funds.

Precision BioSciences Company Profile